Hepatitis B serology is usually read next to liver enzymes such as ALT, because the antigen and antibody results say whether someone is infected, immune or unexposed, while the enzymes say something about how the liver itself is doing.
The test measures a protein from the outer envelope of the hepatitis B virus circulating in blood, and laboratories regard a reactive result as a marker of current infection.
Hepatitis B is a small DNA virus that replicates inside liver cells. Infected cells produce far more of the surface protein than the virus needs, so blood carries large numbers of empty particles built from surface protein alone, alongside any complete virus particles 1. That excess is what makes the protein straightforward to detect with a routine immunoassay, and it is why surface antigen became the first marker most laboratories look for when hepatitis B is a question 2.
Most laboratories report the result qualitatively, as reactive (positive) or non-reactive (negative). Some reports add a signal to cut-off ratio, which describes how strongly the sample reacted in that particular assay rather than how much virus a person carries. A reactive screening result is normally confirmed before it is acted on, either by repeating the assay or by a confirmatory neutralisation step.
Timing matters as much as the result. Surface antigen is usually the first serological marker to appear after exposure, generally before any symptoms and before liver enzymes shift 1. It can also disappear. In most adults whose immune system clears the virus, the protein becomes undetectable over the following months. When surface antigen is still detectable six months later, that persistence is how chronic infection is defined, rather than through any separate test 3.
So the test answers one narrow question well, which is whether the surface protein is in the blood on the day of the draw. It does not say how long it has been there, how the liver is coping, or whether a person is protected. Those questions belong to other markers.
Because it is the single marker that separates current infection from everything else, which is why it sits at the front of almost every hepatitis B testing pathway.
Antibody results describe history. Surface antigen describes the present. A person can have antibodies from vaccination, antibodies from an infection decades ago, or no markers at all, and in each of those situations the surface antigen is non-reactive. The moment it turns reactive, the question changes from what happened in the past to what is happening now, including whether the virus can be passed to other people through blood or sexual contact or from a birth parent to a newborn.
Research suggests that surface antigen testing is the practical anchor of hepatitis B screening programmes, including in settings where laboratory infrastructure is limited and rapid point-of-care tests carry much of the load 4. The same marker underpins blood donation screening, antenatal screening and the assessment of close contacts, because a single reactive result changes what a clinician does next for that person and for the people around them.
It also anchors the interpretation of everything else on the panel. Core antibody without surface antigen reads one way. Core antibody with surface antigen reads another. Surface antibody on its own reads a third way. The antigen result is the pivot the rest of the panel turns on, which is why a hepatitis B panel almost never contains the antibody tests alone.
One caution worth holding on to from the start. A reactive result is a laboratory observation about a protein in blood, not a description of how a liver is functioning. Two people with the same reactive result can be in very different situations, and only further assessment by a clinician separates them.
Surface antibody (anti-HBs) indicates immunity, and core antibody (anti-HBc) indicates that the immune system has met the whole virus at some point.
Surface antibody is the neutralising antibody directed against the same protein the antigen test looks for. It appears after recovery from an infection, and it also appears after vaccination, because vaccination presents the surface protein to the immune system without the rest of the virus 1. A reactive surface antibody result is therefore the marker most people mean when they say they are protected.
Core antibody is directed against an internal protein of the virus, one the immune system only encounters during a real infection. That single difference is what makes the core antibody so useful. Immunity from vaccination produces surface antibody without core antibody. Immunity after a resolved infection produces both 2. Total core antibody usually stays detectable for life once it appears.
Laboratories can also report the IgM subclass of core antibody. IgM core antibody tends to be present early and fade afterwards, so it helps a clinician judge whether an infection is recent rather than long standing, particularly when someone with a reactive surface antigen has no previous results to compare against 1.
Read together, the three results answer three separate questions. Surface antigen asks whether the virus is present now. Core antibody asks whether the body has ever met the real virus. Surface antibody asks whether there is measurable protection. Ordering one without the others is the most common reason people end up with a result they cannot interpret.
Four patterns cover most hepatitis B panels, and each is defined by the combination of the three markers rather than by any single one.
| Pattern | Surface antigen (HBsAg) | Surface antibody (anti-HBs) | Core antibody (anti-HBc) | What laboratories regard this as |
|---|---|---|---|---|
| Susceptible | Non-reactive | Non-reactive | Non-reactive | No marker of infection and no measurable immunity |
| Immune from vaccination | Non-reactive | Reactive | Non-reactive | Immunity from vaccination, with no sign of past infection |
| Immune after a past, resolved infection | Non-reactive | Reactive | Reactive | Recovery from an earlier infection, with antibodies present |
| Current infection | Reactive | Non-reactive | Reactive | Current infection, with recent versus long standing judged using IgM core antibody and repeat testing |
| Needs clinician review | Non-reactive | Non-reactive | Reactive | Several possible explanations, none of them resolvable from this panel alone |
The fourth row is the one most people recognise, and the fifth is the one that generates the most questions. An isolated core antibody result, with both surface markers non-reactive, has more than one explanation and is discussed further below.
Two practical notes. First, these patterns describe a moment in time, and a panel drawn weeks apart can look different, which is exactly why repeat testing is part of the standard pathway. Second, the pattern alone never describes liver health. A person can sit in the current infection row with entirely unremarkable liver enzymes, and a person in the immune row can have liver enzymes that deserve attention for an unrelated reason.
A reactive surface antigen result means the surface protein was detected in that sample, which laboratories regard as a sign of current hepatitis B infection, pending confirmation.
The observation is specific. The meaning depends on context that one draw cannot supply. The first thing a clinician usually establishes is whether the result is confirmed, because screening assays are designed to be sensitive and a small number of reactive screens are not confirmed on follow-up testing. The second is timing. A clinician typically looks at IgM core antibody, any previous results and the clinical picture to judge whether this is recent or long standing, and repeat testing at six months is what formally separates an infection that resolves from one that persists 3.
From there, assessment usually widens. A clinician decides whether to add other viral markers such as the e antigen and viral DNA, liver enzymes and other liver chemistry, and an assessment of the liver itself, along with testing for other infections that share routes of transmission 5. The purpose is to place a confirmed result into a phase and a risk picture, because those determine what monitoring looks like.
A reactive result also has consequences beyond the person tested, because the virus can be transmitted through blood, through sexual contact and around the time of birth. Testing of household members and sexual partners, and vaccination of those who are susceptible, are standard parts of the conversation, and a clinician decides who needs what.
What a reactive result is not is a verdict on a person's liver or their future. Many people with a confirmed reactive result feel entirely well. Any decision about monitoring intervals or treatment belongs to a licensed provider who has reviewed the full picture, and a reactive result should never be set aside simply because nothing feels wrong.
A non-reactive result means the surface protein was not detected in that sample, which in most cases means no current infection, but it says nothing on its own about protection.
This is the result most often misread. People treat non-reactive as a clean bill of health, when all it rules out is detectable surface antigen on the day of the draw. Without a surface antibody result next to it, there is no information about immunity at all, and the susceptible pattern and the vaccinated pattern look identical on the antigen test alone.
There are also three situations where a non-reactive result does not settle the question. The first is very recent exposure, because surface antigen takes time to rise to detectable levels after the virus is acquired, so an early test can be non-reactive while infection is establishing 1. The second is the window between surface antigen disappearing and surface antibody appearing, when core antibody may be the only reactive marker 2. The third is uncommon and assay related, discussed in the section on confusing results.
The useful next step after a non-reactive antigen result is usually the rest of the panel rather than a repeat of the same test. Surface antibody tells a person whether they have measurable protection, core antibody tells them whether they have met the virus before, and a clinician decides whether the timing of any exposure means the panel should be repeated later.
A hepatitis B titer test almost always means a quantitative surface antibody measurement, reported as a number in mIU/mL, used to document immunity rather than to look for infection.
This is the test requested for healthcare students, clinical staff and anyone who needs documented proof of protection. A qualitative surface antibody result says reactive or non-reactive. The titer puts a number on it. Laboratories commonly regard a surface antibody level of 10 mIU/mL or above as the threshold for measurable protection after vaccination, and results are interpreted against that threshold alongside a person's vaccination history 5.
A titer below that threshold is not a statement that a person has no immunity, and it is not a cue for self-directed action. Antibody levels can fall over years even where immune memory persists, and the response to vaccination varies between individuals. What the number does is give a clinician something concrete to work from when deciding whether further vaccination or further testing is appropriate for that person.
Separately, the surface antigen itself can be measured quantitatively in IU/mL, which is a different test used in specialist settings rather than in routine screening. Studies suggest that quantitative surface antigen levels carry information about the phase of chronic infection that a simple reactive or non-reactive result does not 6. This is a clinician-ordered test interpreted alongside viral DNA and liver chemistry, not something a person would request on its own.
The practical distinction is worth remembering. Antibody titer answers whether you are protected. Quantitative antigen answers a question about an infection that has already been confirmed.
Yes. Surface antigen can become undetectable, either after an acute infection resolves or, less often, after years of chronic infection.
In the common pattern, an adult who acquires the virus and clears it loses detectable surface antigen within months and develops surface antibody, leaving the immune after past infection pattern of reactive surface antibody and reactive core antibody 1. Core antibody normally stays detectable afterwards, which is the fingerprint that distinguishes this from vaccine immunity.
In long standing infection, loss of surface antigen happens more slowly and less frequently. Research suggests that loss of surface antigen is associated with a more favourable long term course, while also leaving a case for continued follow-up rather than discharge from monitoring 7. Surface antibody may or may not appear afterwards, and its absence does not undo the antigen loss.
This is one of the clearest illustrations of why a hepatitis B result is a snapshot. A person tested at two points years apart can legitimately move between patterns in the table above, and neither result is wrong. It also explains why clinicians put weight on previous results when they exist. A newly non-reactive antigen in someone with a documented reactive result years earlier means something different from a non-reactive antigen in someone with no history at all.
What does not change is who makes the decisions. Monitoring intervals after antigen loss, and whether anything else is needed, are judgements for a licensed provider who knows the person's full history.
Several recognised situations produce panels that do not fit the four tidy patterns, and all of them are reasons to have results read by a clinician rather than matched against a chart.
The first is isolated core antibody, meaning core antibody reactive with both surface antigen and surface antibody non-reactive. This pattern is associated with past infection in which surface antibody has fallen below the detection threshold, with the window period of a recent infection, and in a minority of people with occult infection, where viral DNA is present at low levels without detectable surface antigen 8. Blood services have examined this pattern closely because of what it means for donated blood 8.
The second is the assay itself. Research suggests that variants in the viral surface gene can alter the part of the protein that an immunoassay binds to, so that an infected person may produce a weakly reactive or even non-reactive surface antigen result on some assays 9. This is uncommon, but it is a real reason why a clinician may order viral DNA testing when the serology and the clinical picture disagree.
The third is timing. Any single panel captures one moment in a sequence that moves. A draw taken soon after exposure, or during the gap between antigen clearance and antibody appearance, can give a technically correct result that is clinically incomplete.
The fourth is documentation. Vaccination history, previous positive results, and recent testing all change how a panel reads, and a laboratory report carries none of that context. Mentioning recent vaccination, recent testing and any prior hepatitis B results to the clinician reviewing the panel is one of the most useful things a person can do.
Hepatitis B serology is almost always read with liver chemistry and, where infection is confirmed, with further viral markers that a clinician selects.
| Marker | What it adds to the picture |
|---|---|
| Surface antibody (anti-HBs) | Whether there is measurable immunity, from vaccination or from a resolved infection |
| Core antibody, total (anti-HBc) | Whether the immune system has ever met the whole virus |
| Core antibody, IgM | Helps a clinician judge whether an infection is recent |
| E antigen and e antibody | Clinician-ordered markers used to describe the phase of a confirmed infection |
| Hepatitis B viral DNA | Measures viral replication directly, ordered by a clinician when serology needs clarifying |
| ALT and AST | Liver enzymes that reflect liver cell turnover |
| Bilirubin, albumin, platelets | Broader liver chemistry a clinician reviews alongside enzymes |
ALT is the enzyme most often reported next to a hepatitis B panel, and it is one of the markers where an optimisation target sits tighter than the standard laboratory range.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| ALT, men | 7 to 56 U/L | 10 to 25 U/L |
| ALT, women | 7 to 33 U/L | 8 to 19 U/L |
Typical reference ranges vary by laboratory, age and sex, and the range printed on your own report is the one your result was interpreted against. FitScript's optimal ranges are optimisation targets rather than diagnostic cut-offs, so a value inside the standard range but outside the optimal range is a prompt for discussion, not a finding in itself. FitScript's membership covers 150+ biomarkers tested per year, with results interpreted by Atlas, FitScript's AI health advisor, and any clinical decision made by a licensed provider.
They describe the liver rather than the virus, which is why they are read next to serology rather than instead of it.
ALT is an enzyme concentrated in liver cells, and the amount circulating in blood reflects liver cell turnover. In the context of hepatitis B, enzyme results help a clinician judge whether there is current liver inflammation, and they are tracked over time rather than judged from one value 5. An unremarkable ALT never rules hepatitis B in or out, and a raised ALT has many possible explanations that have nothing to do with this virus, including recent heavy exercise, alcohol and some medicines, which is a question for your prescriber. The ALT biomarker page covers what the enzyme is, how it is measured and how to read a result in detail.
It is a standard venous blood draw, processed in a laboratory by immunoassay, with no special preparation needed for the serology itself.
Fasting is not required for hepatitis B serology. If the draw is bundled with a metabolic or lipid panel, the fasting instruction belongs to those tests, not to this one. Time of day, hydration and recent meals do not meaningfully change whether antigen or antibody is detected. Turnaround depends on the laboratory and on whether confirmatory testing is triggered, so the practical approach is to ask the ordering service what to expect rather than to work from an assumed timeline.
Rapid point-of-care surface antigen tests also exist and are widely used where laboratory access is limited, with research suggesting they are central to making screening workable in those settings 4. A reactive rapid test is a prompt for laboratory confirmation rather than a final answer.
Two things genuinely affect interpretation. One is timing relative to any exposure, because markers appear in sequence rather than all at once 1. The other is which tests were ordered. A panel containing only surface antigen answers far less than one containing antigen, surface antibody and core antibody together, and the gap is usually only noticed after the result arrives.
Testing decisions are individual, and in practice they follow risk of exposure, pregnancy, and situations where knowing a person's hepatitis B status changes their medical care.
Standard testing pathways include people born in regions where hepatitis B is more common, household members and sexual partners of someone with a reactive result, people who have shared injecting equipment, people on dialysis, people living with HIV, and pregnancy, where antenatal screening is routine. Testing is also standard before some medical therapies that affect immune function, with the prescribing clinician determining the need 5. Research suggests that broad, accessible screening is the limiting step in identifying infection, because most people with chronic hepatitis B have no symptoms that would prompt them to ask 4.
Frequency is the harder question, and it is not one a general rule answers well. Hepatitis B serology is not a marker that is usefully repeated on a fixed schedule for everyone. For most people with a documented immune pattern and no ongoing exposure, there is no routine repeat. For people with ongoing risk, the clinician who knows that risk sets the interval. For anyone with a confirmed reactive antigen, monitoring is a clinical plan rather than a self-scheduled test.
What is worth doing is knowing your own status rather than assuming it. Many people believe they were vaccinated in childhood and have never seen a surface antibody result confirming a response. A single panel settles the question, and the answer rarely needs revisiting without a reason.
A confirmed or unexpected reactive surface antigen result is worth discussing with a clinician promptly, as is any hepatitis B result that arrives alongside new symptoms.
The clearest prompts are a reactive surface antigen in someone who did not know their status, an isolated core antibody pattern, a result that conflicts with a previous one, and any panel drawn after a known exposure. None of these are emergencies by default, and none of them should be left sitting in an inbox either. The sensible interval is days, not months.
Symptoms change the urgency. Yellowing of the skin or eyes, dark urine, pale stools, persistent right upper abdominal discomfort, unusual fatigue, easy bruising or new swelling are all reasons to contact a clinician promptly rather than waiting for a scheduled appointment, whatever the serology shows. A broader overview of signs of liver problems is worth reading alongside your results, bearing in mind that symptoms are a late and unreliable signal in liver conditions.
It is also worth saying plainly what not to do. Do not set aside an abnormal result because you feel well, do not interpret a single value as a diagnosis, and do not start or stop anything on the basis of a laboratory report. In people with confirmed chronic hepatitis B, decisions about monitoring intervals and about whether any therapy is appropriate belong to a licensed provider who has reviewed the whole picture, and treatment decisions belong to a licensed provider.
This page is educational and is not medical advice. Discuss your own results, and any treatment question they raise, with a clinician or licensed provider who can review your full history.
It means the surface protein of the hepatitis B virus was detected in that blood sample, which laboratories regard as a sign of current infection. A reactive screening result is normally confirmed before anything is decided on it. The next steps, including repeat testing and any additional markers, are chosen by a clinician who reviews your history.
The antigen is part of the virus itself, so detecting it points to current infection. The antibody is made by your immune system against that protein, so detecting it points to immunity, either from vaccination or from an infection that resolved. They are separate tests and they answer opposite questions.
Yes. Core antibody appears only after contact with the whole virus, so someone who had an infection and recovered usually has both core antibody and surface antibody. Immunity from vaccination produces surface antibody without core antibody. That difference is how a clinician tells the two kinds of immunity apart.
It usually means a quantitative surface antibody result, reported as a number, used to document whether you have measurable immunity. Healthcare workers, students and people entering clinical settings are often asked for it. A result below the threshold your laboratory uses is a reason to speak with a clinician, not a reason to act on your own.
No. Hepatitis B serology does not require fasting, and food, hydration or time of day do not change whether the markers are detected. If your draw is combined with a metabolic or lipid panel, any fasting instruction comes from those tests. Follow whatever the ordering service tells you.
No. A non-reactive antigen result only means the viral protein was not detected on the day of the draw. Protection is shown by the surface antibody result, which is a separate test. Without it, someone who has never been exposed and someone who is fully vaccinated can look identical.
The markers appear in sequence rather than immediately, so a test taken very soon after a possible exposure can come back non-reactive while an infection is still establishing. That is why a single early panel does not close the question. A clinician decides whether and when the panel should be repeated.
Yes. In most adults who clear an acute infection, the antigen becomes undetectable within months and surface antibody appears. In long standing infection, the antigen can also be lost, though this happens more slowly and less often. Because the picture moves, previous results matter and repeat testing is part of the standard pathway.